3-benzyl-1,6-dimethyl-pyrimido[5,4-e][1,2,4]triazine-5,7-dione | 878419-53-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 3-benzyl-1,6-dimethyl-pyrimido[5,4-e][1,2,4]triazine-5,7-dione
• 英文别名: 3-benzyl-1,6-dimethyl-1H,5H,6H,7H-pyrimido[5,4-e][1,2,4]triazine-5,7-dione；3-benzyl-1,6-dimethylpyrimido[5,4-e][1,2,4]triazine-5,7-dione
• CAS: 878419-53-5
• 化学式: C₁₄H₁₃N₅O₂
• 分子量: 283.29
• InChiKey: PIDBTJWOPOMOMX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  77.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  3-甲基-6-(1-甲基肼基)-2,4(1H,3H)-嘧啶二酮 在 溶剂黄146 、 sodium nitrite 作用下， 以 乙醇 、 水 为溶剂， 反应 2.0h， 生成 3-benzyl-1,6-dimethyl-pyrimido[5,4-e][1,2,4]triazine-5,7-dione
  参考文献：
  名称：

  一类蛋白质二硫键异构酶抑制剂治疗胶质母细胞瘤的发现和机理研究

  摘要：

  蛋白质二硫键异构酶（PDI）在胶质母细胞瘤（脑癌的最具侵略性形式）中过表达，并且折叠负责该疾病进展和传播的新生蛋白质。在这里，我们描述了一种新型的纳摩尔PDI抑制剂，嘧啶三嗪二酮35G8，在一组人胶质母细胞瘤细胞系中具有毒性。我们对1 000 000种化合物的不同子集进行了中通量20000化合物筛查，以鉴定具有细胞毒性的小分子。对细胞毒性化合物进行了PDI抑制作用的筛选，并且从筛选物中发现35G8是PDI最具细胞毒性的抑制剂。新生RNA的溴尿苷标记和测序（Bru-seq）表明35G8诱导类似核因子2（Nrf2）的抗氧化反应，内质网（ER）应激反应和自噬。具体而言，35G8上调了血红素加氧酶1和溶质载体家族7成员11（SLC7A11）的转录和蛋白质表达，并抑制了PDI靶基因，如硫氧还蛋白相互作用蛋白1（TXNIP）和早期生长反应1（EGR1）。有趣的是，35G8诱导的细胞死亡不是通过细胞凋亡

  DOI：

  10.1002/cmdc.201700629

文献信息

• Rational design, synthesis and biological profiling of new KDM4C inhibitors
  作者：Vatroslav Letfus、Dubravko Jelić、Ana Bokulić、Adriana Petrinić Grba、Sanja Koštrun

  DOI：10.1016/j.bmc.2019.115128

  日期：2020.1

  diseases such as prostate and breast cancer. Majority of currently known inhibitors suffer from the low permeability and low selectivity between the enzyme isoforms. In this study, toxoflavin motif was used to design and synthesize new KDM4C inhibitors with improved biological activity and in vitro ADME properties. Inhibitors displayed good passive cellular permeability and metabolic stability. However

  KDM4家族的人组蛋白脱甲基酶已经与诸如前列腺癌和乳腺癌的疾病有关。当前已知的大多数抑制剂都遭受酶同工型之间的低渗透性和低选择性。在这项研究中，毒素黄素被用于设计和合成具有改善的生物活性和体外ADME特性的新型KDM4C抑制剂。抑制剂表现出良好的被动细胞通透性和代谢稳定性。然而，减少氧化还原责任并因此对细胞生存力的非特异性影响仍然是一个挑战。
• Toxoflavins and Deazaflavins as the First Reported Selective Small Molecule Inhibitors of Tyrosyl-DNA Phosphodiesterase II
  作者：Ali Raoof、Paul Depledge、Niall M. Hamilton、Nicola S. Hamilton、James R. Hitchin、Gemma V. Hopkins、Allan M. Jordan、Laura A. Maguire、Alison E. McGonagle、Daniel P. Mould、Mathew Rushbrooke、Helen F. Small、Kate M. Smith、Graeme J. Thomson、Fabrice Turlais、Ian D. Waddell、Bohdan Waszkowycz、Amanda J. Watson、Donald J. Ogilvie

  DOI：10.1021/jm400568p

  日期：2013.8.22

  The recently discovered enzyme tyrosyl-DNA phosphodiesterase 2 (TDP2) has been implicated in the topoisomerase-mediated repair of DNA damage. In the clinical setting, it has been hypothesized that TDP2 may mediate drug resistance to topoisomerase II (topo II) inhibition by etoposide. Therefore, selective pharmacological inhibition of TDP2 is proposed as a novel approach to overcome intrinsic or acquired resistance to topo II-targeted drug therapy. Following a high-throughput screening (HTS) campaign, toxoflavins and deazaflavins were identified as the first reported sub-micromolar and selective inhibitors of this enzyme. Toxoflavin derivatives appeared to exhibit a clear structure-activity relationship (SAP.) for TDP2 enzymatic inhibition. However, we observed a key redox liability of this series, and this, alongside early in vitro drug metabolism and pharmacokinetics (DMPK) issues, precluded further exploration. The deazaflavins were developed from a singleton HTS hit. This series showed distinct SAR and did not display redox activity; however low cell permeability proved to be a challenge.
• [EN] INHIBITORS OF CYSTATHIONINE BETA SYNTHASE TO REDUCE THE NEUROTOXIC OVERPRODUCTION OF ENDOGENOUS HYDROGEN SULFIDE<br/>[FR] INHIBITEURS DE CYSTATHIONINE BÊTA-SYNTHASE POUR RÉDUIRE LA SURPRODUCTION NEUROTOXIQUE DE SULFURE D'HYDROGÈNE ENDOGÈNE
  申请人：FOND JEROME LEJEUNE

  公开号：WO2010072807A2

  公开（公告）日：2010-07-01

  The invention is directed to inhibitors of cystathionine beta synthase which, among other biochemical effects, allow reduction of the neurotoxic overproduction of endogenous hydrogen sulphide. These compounds and pharmaceutical compositions containing them are useful for the prevention and treatment of neurotoxic and cognitive disorders such as cognitive disorders in Down syndrome. The invention also relates to methods for preventing or treating neurotoxic and cognitive disorders including cognitive disorders in Down Syndrome.
• Discovery and Mechanistic Elucidation of a Class of Protein Disulfide Isomerase Inhibitors for the Treatment of Glioblastoma
  作者：Anahita Kyani、Shuzo Tamura、Suhui Yang、Andrea Shergalis、Soma Samanta、Yuting Kuang、Mats Ljungman、Nouri Neamati

  DOI：10.1002/cmdc.201700629

  日期：2018.1.22

  Protein disulfide isomerase (PDI) is overexpressed in glioblastoma, the most aggressive form of brain cancer, and folds nascent proteins responsible for the progression and spread of the disease. Herein we describe a novel nanomolar PDI inhibitor, pyrimidotriazinedione 35G8, that is toxic in a panel of human glioblastoma cell lines. We performed a medium‐throughput 20 000‐compound screen of a diverse

  蛋白质二硫键异构酶（PDI）在胶质母细胞瘤（脑癌的最具侵略性形式）中过表达，并且折叠负责该疾病进展和传播的新生蛋白质。在这里，我们描述了一种新型的纳摩尔PDI抑制剂，嘧啶三嗪二酮35G8，在一组人胶质母细胞瘤细胞系中具有毒性。我们对1 000 000种化合物的不同子集进行了中通量20000化合物筛查，以鉴定具有细胞毒性的小分子。对细胞毒性化合物进行了PDI抑制作用的筛选，并且从筛选物中发现35G8是PDI最具细胞毒性的抑制剂。新生RNA的溴尿苷标记和测序（Bru-seq）表明35G8诱导类似核因子2（Nrf2）的抗氧化反应，内质网（ER）应激反应和自噬。具体而言，35G8上调了血红素加氧酶1和溶质载体家族7成员11（SLC7A11）的转录和蛋白质表达，并抑制了PDI靶基因，如硫氧还蛋白相互作用蛋白1（TXNIP）和早期生长反应1（EGR1）。有趣的是，35G8诱导的细胞死亡不是通过细胞凋亡